Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559363 | 0.88 | CTBP2 (0.49) | CTBP2FFAR1POLBALDH1A1KMT2A | |
| SCHEMBL18827717 | 0.85 | CTBP2 (0.47) | CTBP2FFAR1POLBALDH1A1KMT2A | |
| SCHEMBL10266902 | 0.84 | FFAR1 (0.44) | CTBP2FFAR1POLBALDH1A1KMT2A | |
| SCHEMBL10196980 | 0.82 | CTBP2 (0.51) | CTBP2FFAR1POLBALDH1A1KMT2A | |
| SCHEMBL822636 | 0.82 | TSHR (0.51) | POLBALDH1A1KMT2AL3MBTL1HPGD | |
| SCHEMBL10196961 | 0.81 | HPGD (0.46) | CTBP2FFAR1POLBALDH1A1KMT2A | |
| SCHEMBL10137770 | 0.80 | CTBP2 (0.54) | CTBP2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL10196954 | 0.78 | CYP1A2 (0.46) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL1107143 | 0.76 | KMT2A (0.56) | CTBP2POLBALDH1A1KMT2APKM | |
| SCHEMBL10196963 | 0.76 | ALDH1A1 (0.41) | POLBALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CTBP2 1615/4885FFAR1 2502/4885POLB 4189/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CTBP2 1615/4885FFAR1 2502/4885POLB 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.